Introduction
Esophageal atresia (EA) occurs with frequency of 1 in 2,500 to 4,500 live births. [1] [2] [3] [4] Adult patients born with EA have high incidence rates of gastroesophageal reflux symptoms as well as histological signs of esophagitis and Barrett's esophagus (BE). [5] [6] [7] BE is considered as a preneoplastic condition and a risk factor for developing esophageal adenocarcinoma (EAC), a very often deadly cancer. [8] [9] [10] To date, there has been at least eight reported cases of esophageal cancer: three EACs and five esophageal squamous cell carcinomas (ESCCs). [11] [12] [13] [14] [15] [16] [17] Due to an increased risk of developing EAC in these patients, early
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Abstract
Background Previous studies have reported an association among esophageal atresia (EA), Barrett's esophagus, and esophageal adenocarcinoma later in life. Objective The objective of the article is to evaluate KRAS and BRAF mutations as potential genetic markers for early detection of malignant transformation, we used an ultrasensitive technique to detect tissue expression of KRAS and BRAF mutations in endoscopic biopsies from 61 adult patients under follow-up after treatment for EA. Materials and Methods RNA was extracted from 112 fresh-frozen endoscopic tissue biopsies from 61 adult patients treated for EA in early childhood. RNA was reverse transcribed using the extendable blocking probe reverse transcription method. KRAS codons 12 and 13, as well as BRAF mutations were detected by quantitative polymerase chain reaction. Results No mutations of KRAS codon 12, KRAS codon 13, or BRAF were found in 112 endoscopic biopsy samples from 61 patients. Conclusion Despite the presence of histological findings indicating long-standing gastroesophageal reflux in 25%, as well as symptomatic gastroesophageal reflux in more than 40%, there was no detectable tissue expression of KRAS or BRAF mutations in this cohort of patients.
and lifelong surveillance programs including endoscopic biopsies have been suggested to enable early detection of malignant transformation.
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The Ras-Raf-MEK-ERK-MAPK pathway (MAPK/ERK pathway) is currently regarded as one of the most important pathways in cancer development. The KRAS and BRAF genes are members of the MAPK/ERK pathway, and mutations in these genes are found in 30 and 8%, respectively, of human tumors.
19-21 KRAS and BRAF mutations have been demonstrated to be genetic markers in lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer, including prostate and gastric cancers. 22 The role of these oncogenes in the development and progression of BE into EAC remains unclear.
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Although recently a new study performed whole exome sequencing on 149 EAC and found no evidence of BRAF mutations and only 2 to 3% of EAC had KRAS mutations. To evaluate KRAS and BRAF mutations as early genetic markers for malignant transformation in patients treated for EA, we have utilized the ExBP-RT technique to determine the incidence of tissue expression of KRAS and BRAF mutations in endoscopic biopsies from adult patients treated for EA in early childhood.
Materials and Methods

Patients and Clinical Data
During the time period 2001 to 2004, 112 endoscopic biopsies were collected prospectively from 61 patients treated for EA in early childhood at the Hospital for Children and Adolescents, Helsinki University Central Hospital. The age at biopsy was 21 to 56 years (mean: 35.6, median: 32.7 years). Thirty-five of the patients were males and 26 were females. The distribution of the type of EA was EA with proximal tracheoesophageal fistula (TEF): 1.6%, distal TEF: 90.2%, proximal and distal TEFs: 4.9% and H-type TEF: 3.3%. Out of 61 patients, 6 had a long-gap disease as defined by a distance between the upper and lower pouches of more than 3 cm or at least two vertebral bodies on plain radiography. Out of 61 patients, 10 had tracheomalacia. Six patients had been reoperated due to a fistula. Of 61 patients, 59 in this cohort had undergone dilatations of the esophageal anastomosis (range: 0-66, mean: 11.8, median: 8). Four patients had undergone surgical resection of a stricture and 10 patients had undergone a fundoplication. Biopsies were taken 2 cm above the esophagogastric junction. Histological examination of the biopsy specimens showed esophagitis in 5 of 61 cases, gastric metaplasia in 10 of 61, and intestinal metaplasia in 5 of 61 cases. Informed consent was received from all patients participating in this study in accordance with the Helsinki declaration. The study was approved by the ethics committee of the Hospital for Children and Adolescents, University of Helsinki, Finland.
RNA Samples
Endoscopic biopsy samples were collected in RNALater and stored at 4°C until extraction within 1 week from sampling. RNA was extracted from all 112 sample biopsies from 61 patients using phenol-chloroform extraction 34 and stored at À80°C. Before the ExBP-RT reaction, all RNA samples were quantified with a NanoVue spectrophotometer (GE Healthcare, Waukesha, Wisconsin, United States) then diluted to 100 ng/μL in diethylpyrocarbonate (DEPC) H 2 O. RNA extracted from A549, Lovo, and Colo205 cell lines was used as positive and negative controls, respectively (►Table 1). All control RNAs were extracted from cell cultures using RNA/DNA purification kit (Norgen Biotek) then quantified with a NanoVue spectrophotometer and diluted to 100 ng/μL in DEPC H 2 O before using.
ExBP-RT-Based Mutation Detection Assays
ExBP-RT 33 was employed for ultrasensitive detection of most common mutations of the KRAS and BRAF genes. Using RNA templates, this novel method allows for detection of expressed mutations in at least a 1,000 times higher background of the corresponding wild-type alleles. Mutations covered in this study include six different common KRAS mutations at codon 12 (G12D, G12A, G12V, G12S, G12A, and G12C); one KRAS mutation at codon 13 (G13D); and one BRAF mutation (V600E). The principles of ExBP-RT assays and reaction setup procedures for multiplex detection of six KRAS mutations at codon 12 and one BRAF mutation (V600E) were as described in the original article. 33 ExBP-RT primers and probe for detection of KRAS mutation at codon 13 (G13D) are listed in ►Table 2.
Detection and Quantification of Expressed Mutations
Using products of the ExBP-RT assays as template, real-time PCR amplification was performed to detect/quantify expressed mutations of KRAS and BRAF genes. QuantiTect Probe PCR Kits (QIAGEN) were used for these probe-based real-time PCR assays according to the manufacturer's instructions in a 10-µL reaction volume. The Taqman probes for simultaneous detection of six different KRAS mutations at codon 12 were designed to contain two universally binding inosine nucleotides that allows for targeting the variant nucleotides of different types of mutation. A common reverse primer was designed to target the 5′-prime tail of all mutation-specific ExBP-RT products. The expression levels of total KRAS and total BRAF genes (both mutant and wild type) were also determined in each sample for normalization using QuantiTect SYBR Green PCR Kits (QIAGEN) according to the manufacturer's instructions in a 10-µL volume. The sequences and concentration of quantitative PCR (qPCR) primers and probes are provided in ►Table 3.
The same thermocycling conditions were used for both probebased and SYBR-based qPCRs: 951C for 15 minutes, 45 cycles at 941C for 10 seconds, and at 601C for 45 seconds. Following SYBR-based qPCR, the specificity of the amplification products was always verified by melting curve analysis. All qPCR assays were run on a LightCycler 480 II Instrument real-time PCR (Roche Diagnostics Oy, Finland) with 384-well white plate. All mutation controls, wild-type controls, and H 2 O controls of each experiment were checked to verify the correction of results in both ExBP-RT and qPCR assays and avoid the problem of contamination. We calculated threshold cycle (C t ) values of qPCR automatically using the absolute quantification analysis with the fit points method, which is built in the LightCycler 480 II system (Roche Diagnostics Oy). That allows to set the noise band and the threshold line to discard uninformative background noise.
Results
In this study, we retrospectively examined 112 endoscopic tissue biopsies from 61 adult patients under follow-up after surgical treatment for EA. To verify the viability of the RNA samples, the total tissue expression levels of the KRAS and BRAF genes were analyzed by real-time PCR with primer pairs that coamplifies both mutant and wild-type cDNAs generated in ExBP-RT assays. Tissue expression of the KRAS and BRAF genes could be readily detected in all 112 samples (►Fig. 1). Mutation controls consisting of RNA extracted from cell lines that express KRAS mutation at codon 12 (A549), KRAS mutation at codon 13 (Lovo), and BRAF mutation (Colo205) could be readily detected in every experiment (►Fig. 2). Expression of KRAS codon 12, codon 13, or BRAF mutations was, however, not detected in any of the 112 patient samples.
Discussion
EA is a developmental disorder, where in most cases, the upper and lower ends of the esophagus have failed to unite and the innervation to the distal part of the esophagus is disrupted. Surgical repair of EA is not believed to restore innervation and a certain degree of gastroesophageal reflux disease thus, occurs from birth in most EA patients. This is thought to play a role in the development of BE through repeated mucosal damage.
32,35
Replacement of the normal squamous epithelium by intestinalized columnar epithelium in BE is considered a preneoplastic condition that predisposes to EAC 8 and the association among EA, BE, and EAC has been well established. 5, 32 In this study, we strived to clarify whether KRAS or BRAF mutations would be present at detectable levels in patients previously treated for EA. The rationale was that the presence of expressed KRAS or BRAF mutations, that should not be present in healthy tissues, could be used for early identification of patients at risk of developing EAC. For this purpose, we utilized a novel RNA-based technique, ExBP-RT, for point mutation detection with high sensitivity compared with DNA-based techniques.
33
KRAS and BRAF mutations are predominantly found in cancers arising from abnormal columnar epithelium, such as colorectal cancer and pancreatic cancer. KRAS mutations are found in 30 to 60% of colorectal cancers, [36] [37] [38] and they are present in more than 90% of pancreatic ductal adenocarcinomas. 39 BRAF mutations are present in colorectal cancer with frequency of 10 to 15%. 40 In ESCCs and basaloid squamous cell carcinomas, KRAS and BRAF mutations are rare or absent, [41] [42] [43] [44] suggesting that these mutations play a limited role in the development of ESCC. 41 In EAC and associated high-grade intraepithelial lesions, however, KRAS codon 12 mutations occur at a frequency between 30 and 40%, and might represent a late event in the Barrett's metaplasiadysplasia-adenocarcinoma sequence. 23 KRAS codon 13 and BRAF mutations are known to play a less important role in the development of digestive tract cancers. These mutations seem to be rare in EAC and may not be involved in the development of BE and EAC. We have established ExBP-RT assays for detection of the six most common mutations at KRAS codons 12 and 13, and one common mutation of BRAF V600. These mutations represent 97% (94.5-99.6%) of KRAS and 72% (47-96%) of BRAF mutations that have been described. To the best of our knowledge, this is the first study describing the mutational status of KRAS and BRAF in patients treated for EA.
In this study, we could not detect tissue expression of KRAS or BRAF mutations in any of the 112 endoscopic biopsies from 61 patients treated for EA. While histological analysis revealed gastric metaplasia in 10 out of 61 cases and intestinal metaplasia in further 5 out of 61 cases, neither dysplasia nor EAC was found in any of these patients. In a previous study by Trautmann et al, KRAS codon 12 mutations were only found in 1 out of 252 (0.4%) metaplasia patients and 4 out of 105 (3.8%) dysplasia patients. 26 In addition,
Arber et al detected KRAS mutations in only 1 out of 39 (2%) patients with BE. 42 Our results are consistent with these findings, implying that KRAS codon 12 mutations are rare or absent in preneoplastic conditions of the esophagus.
23
Despite of the previously reported prevalence of KRAS codon 12 mutations in about one-third of EAC tumors and high-grade intraepithelial lesions, we could not detect tissue expression of KRAS or BRAF mutations in any of the 112 biopsy specimens from 61 adult patients treated for EA. We have previously shown that KRAS codon 12 mutations could be detected in 16 out of 44 (36.4%) archival colorectal cancer formalin-fixed paraffin-embedded (FFPE) specimens. This corresponds to a slightly higher mutation rate than previously reported (27.7%) using DNA-based mutation detection assays 45 and subsequent analyses of 775 samples are coherent with these findings (unpublished results). The sensitivity to detect rare mutations with the ExBP-RT assay is thus slightly higher than that of conventional DNA-based assays. At the time of sampling, the mean age of this cohort of patients was 35.6 years and the negative results reported here might reflect the fact that no malignant transformation had taken place in any of the 61 patients included in the study. Our results, however, imply that mutations in the KRAS and BRAF genes alone might not be ideal markers for malignant transformation in patients with EA. It is likely that future studies will reveal genetic markers or combinations of markers that can reveal signs of malignant transformation at an early stage to identify patients in need of close follow-up or early intervention. P53 mutations, which are the most common mutations found in EAC is a potential candidate that should be included in such investigations.
In conclusion, we have utilized a highly sensitive technique to detect tissue expression on mutated KRAS and BRAF genes in endoscopic esophageal biopsies from 61 patients previously treated for EA. The absence of KRAS and BRAF mutations gives no indication of malignant transformation in this cohort of patients. We hope that this study can serve as an inspiration for developing techniques for preventive follow-up of patients treated for EA. 
